Paratek Pharmaceuticals Stock Forecast, Price & News

Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions

Is Paratek Pharmaceuticals a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Paratek Pharmaceuticals stock.
View analyst ratings for Paratek Pharmaceuticals or view top-rated stocks.

How has Paratek Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Paratek Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PRTK stock has increased by 2.6% and is now trading at $3.99.
View which stocks have been most impacted by COVID-19.

When is Paratek Pharmaceuticals' next earnings date?

Paratek Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Paratek Pharmaceuticals.

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) posted its quarterly earnings results on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.45) by $0.08. The specialty pharmaceutical company earned $24.45 million during the quarter, compared to the consensus estimate of $22.98 million. During the same quarter in the previous year, the business earned ($0.46) earnings per share.
View Paratek Pharmaceuticals' earnings history.

What guidance has Paratek Pharmaceuticals issued on next quarter's earnings?

Paratek Pharmaceuticals updated its FY 2021 earnings guidance on Monday, December, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $128 million-$139 million, compared to the consensus revenue estimate of $135.17 million.

What price target have analysts set for PRTK?

4 brokerages have issued 12 month target prices for Paratek Pharmaceuticals' shares. Their forecasts range from $10.00 to $27.00. On average, they anticipate Paratek Pharmaceuticals' stock price to reach $16.50 in the next twelve months. This suggests a possible upside of 313.5% from the stock's current price.
View analysts' price targets for Paratek Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Paratek Pharmaceuticals' key executives?

Paratek Pharmaceuticals' management team includes the following people:

• Evan Loh, Chief Executive Officer & Director (LinkedIn Profile)
• Adam Woodrow, President & Chief Commercial Officer (LinkedIn Profile)
• Sarah Higgins, VP, Chief Financial & Accounting Officer
• Raj Padmanabhan, Vice President-Information Technology
• Paul McGovern, Vice President-Clinical & Medical Affairs

Who are some of Paratek Pharmaceuticals' key competitors?

Some companies that are related to Paratek Pharmaceuticals include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Eli Lilly and (LLY), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT) and Supernus Pharmaceuticals (SUPN).
View all of PRTK's competitors.

What other stocks do shareholders of Paratek Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), CBL & Associates Properties (CBL), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Aduro Biotech (ADRO), Corbus Pharmaceuticals (CRBP) and Rigel Pharmaceuticals (RIGL).

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $3.99.

How much money does Paratek Pharmaceuticals make?

Paratek Pharmaceuticals has a market capitalization of $194.69 million and generates $46.92 million in revenue each year. The specialty pharmaceutical company earns $-96.54 million in net income (profit) each year or ($1.10) on an earnings per share basis.

How many employees does Paratek Pharmaceuticals have?

Paratek Pharmaceuticals employs 197 workers across the globe.

When was Paratek Pharmaceuticals founded?

Paratek Pharmaceuticals was founded in 1996.

What is Paratek Pharmaceuticals' official website?

The official website for Paratek Pharmaceuticals is www.paratekpharma.com.

Where are Paratek Pharmaceuticals' headquarters?

Paratek Pharmaceuticals is headquartered at 75 PARK PLAZA, BOSTON MA, 02116.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at (617) 807-6600, via email at [email protected], or via fax at 617-275-0039.